Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2026-07-21 18:13:18 ET · period of report 2026-07-20 · accession 0001213900-26-080133 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TI | 2026-07-21 18:13 | 2026-07-20 | MLTX | Reich Kristian | CSO | S - Sale | $20.09 | -43.7K | 2.76M | -2% | -$877.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2026-07-20 | S | D | 43,700 | $20.09 | 2,764,746 | I See footnote. | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH. |